Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry.

Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, Seifried E, Schächinger V, Dimmeler S, Zeiher AM; TOPCARE-CHD Registry.

Circ Res. 2007 Apr 27;100(8):1234-41. Epub 2007 Mar 22.

2.

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.

J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. Epub 2007 Oct 29.

3.

N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.

Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA.

Eur Heart J. 2003 Oct;24(19):1735-43.

PMID:
14522568
5.

Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure.

Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS.

Clin Chem. 2009 Jan;55(1):78-84. doi: 10.1373/clinchem.2008.108928. Epub 2008 Nov 21.

6.

Cardiac biomarkers and survival in haemodialysis patients.

Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, Zeier M.

Eur J Clin Invest. 2007 May;37(5):350-6.

PMID:
17461980
7.
8.

Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide.

Jarai R, Iordanova N, Jarai R, Raffetseder A, Woloszczuk W, Gyöngyösi M, Geyer G, Wojta J, Huber K.

Eur Heart J. 2005 Feb;26(3):250-6. Epub 2004 Dec 20.

PMID:
15618049
9.

[Comparison study on diagnostic and prognostic value of N-terminal pro-brain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].

Li YJ, Wang L, Chen KY, Chen YL, Cai JR, Zhou LJ.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005 Sep;17(9):544-7. Chinese.

10.
11.

Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.

Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL.

Eur Heart J. 2009 May;30(9):1057-65. doi: 10.1093/eurheartj/ehn600. Epub 2009 Jan 23.

PMID:
19168526
12.

Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.

Toblli JE, Lombraña A, Duarte P, Di Gennaro F.

J Am Coll Cardiol. 2007 Oct 23;50(17):1657-65.

13.
14.

NT-proBNP, IGF-I and survival in patients with chronic heart failure.

Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R, Fontanella L, de Caterina M, de Simone A, Bonaduce D.

Growth Horm IGF Res. 2007 Aug;17(4):288-96. Epub 2007 Mar 23.

PMID:
17383209
15.

N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.

Kwon TG, Bae JH, Jeong MH, Kim YJ, Hur SH, Seong IW, Cho MC, Seung KB, Jang YS, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

Int J Cardiol. 2009 Apr 3;133(2):173-8. doi: 10.1016/j.ijcard.2007.12.022. Epub 2008 Feb 20.

PMID:
18281115
16.

Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schächinger V, Lehmann R, Martin H, Burck I, Urbich C, Dimmeler S, Zeiher AM, Assmus B.

Clin Res Cardiol. 2011 Oct;100(10):925-34. doi: 10.1007/s00392-011-0327-y. Epub 2011 Jun 3.

PMID:
21633921
17.

Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease.

Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R.

Am J Cardiol. 2008 Aug 15;102(4):469-74. doi: 10.1016/j.amjcard.2008.03.082. Epub 2008 May 24.

PMID:
18678308
18.

N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study.

Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators.

Circulation. 2007 Jun 19;115(24):3103-10. Epub 2007 Jun 4.

19.

N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.

Rutten JH, Steyerberg EW, Boomsma F, van Saase JL, Deckers JW, Hoogsteden HC, Lindemans J, van den Meiracker AH.

Am Heart J. 2008 Jul;156(1):71-7. doi: 10.1016/j.ahj.2008.02.021. Epub 2008 May 27.

PMID:
18585499
20.

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.

Am J Cardiol. 2008 Sep 15;102(6):733-7. doi: 10.1016/j.amjcard.2008.04.048. Epub 2008 Jul 9.

PMID:
18773998

Supplemental Content

Support Center